|
Boston Scientific has financial results for the fourth quarter and full year, which ended Dec. 31, 2009, indicating a reduction in net losses for both.
The Harvard Clinical Research Institute (HCRI) has reported that the first patients have been enrolled in the DAPT [dual-antiplatelet therapy] Study, marking the official initiation of the four-year clinical trial to investigate the duration of dual-antiplatelet therapy following drug-eluting stent (DES) implantations.
The long-awaited SPRIT IV one-year results, presented at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francicso, for Abbott’s Xience V drug-eluting stent (DES) over Boston Scientific’s Taxus DES found a stent thrombosis rate of 0.29 percent, which surprised even Chuck Simonton, Abbott’s chief medical officer.
SAN FRANCISCO—An Asian multicenter study found coronary drug-eluting stents (DES) effective for patients with chronic total occlusions (CTOs), and a low rate of acute complications. The data were presented this week at the 2009 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
The 21 st annual scientific symposium of the Transcatheter Cardiovascular Therapeutics (TCT) meeting will open on Monday in San Francisco. Gregg W. Stone, MD, immediate past-chairman of the Cardiovascular Research Foundation, which sponsors TCT, highlighted some of the trials and important sessions at next week’s show.
Boston Scientific has received FDA approval to market its Taxus Liberte Long paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for long lesions.
Boston Scientific has received approval from the FDA to market its Taxus Liberte Atom paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for treating small coronary vessels, as small as 2.25 mm in diameter.
ORLANDO, Fla.—A large, randomized, controlled multicenter study in Korea found that the second-generation Endeavor drug-eluting stent (DES) was not inferior to the first-generation Cypher DES but was superior in several ways to the first-generation Taxus DES, according to research presented during the i2 Summit at the American College of Cardiology (ACC) 58th annual scientific session.
|
Due to stronger sales, Boston Scientific has booked large (unaudited) net gains in the 2009 third quarter, which ended Sept. 30.
HORIZONS AMI, which studied 3,602 STEMI patients who underwent primary PCI after two years, continued to find a statistically significant superiority for initial treatment with bivalirudin alone compared with heparin plus GPIIb/IIIa inhibitors, and for drug-eluting stents over bare-metal stents. The study was presented during the late-breaking clinical trials at the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco on Sept. 25.
Boston Scientific will pay Cordis $716.3 million to resolve more than a dozen lawsuits over the Palmaz infringement suit relating to Boston Scientific’s NIR stent and several other cardiology cases relating to patents in the Ding, Kastenhofer, Palmaz and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.
SAN FRANCISCO—There is added accumulation of neointima, or so-called late catch-up, after six to nine months in patients who received drug-eluting stents (DES), according to an analysis presented this week at the 2009 Transcatheter Cardiovascular Therapeutics scientific meeting.
Boston Scientific has reported positive financial earnings for its fiscal 2009 second quarter, which ended June 30. The Natick, Mass.-based medical device company booked a net income of $158 million this quarter, compared with $98 million in the second quarter of 2008.
Stents coated with paclitaxel (Taxus from Boston Scientific) may be a safe, effective treatment option for coronary artery disease (CAD) patients age 70 and older, and should not be withheld due to advanced patient age, according to a study reported in the June 2 issue of Circulation: Cardiovascular Interventions.
Boston Scientific launched its platinum chromium Taxus Element paclitaxel-eluting coronary stent system in select international markets. The Taxus Element Stent features a new platinum chromium alloy engineered for coronary stent applications and represents the company's third-generation drug-eluting stent technology.
ORLANDO, Fla.--In patients with ST-elevation MI (STEMI), TAXUS stents significantly reduce neointimal hyperplasia compared to bare-metal stents, but also result in a high frequency of late acquired stent malapposition, according to a substudy of HORIZONS-AMI presented Sunday at the i2 Summit at the American College of Cardiology's (ACC) 58th annual scientific session.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.
There are cases presented to all physicians when we have to balance benefits of a particular treatment with concerns around safety for certain patients. In interventional cardiology, we see this dilemma with drug-eluting stents (DES). While this technology provides effective therapy for many patients with ischemia-inducing coronary lesions, there are certain patient groups that encounter problems for different reasons.
U.S. News & World Report and HealthGrades surveys that rank “Best Hospitals” according to their high-quality cardiovascular care do not create the most comprehensive list and may create confusion by excluding hospitals that provide the same quality of care, according to a study published in the January issue of the Journal of the American College of Surgeons.